This finding suggests a close follow-up strategy in HBsAg-positive patients as well as HBsAg-negative but anti-HBc-, HBeAg-, or anti-HBe-positive MM patients, plus early initiation of active antiviral therapy. The gene discussed is KRT88P; the disease is Miyoshi myopathy.